Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — Investor Presentation (November 2013)

52 slides from Aspen Pharmacare's investor presentation, November 2013

  1. Slide 1: Regional Leader Investor Presentation

    Regional Leader Investor Presentation November 2013

  2. Slide 2: Aspen Asia Pacific

    Aspen Asia Pacific Presented by Greg Lan & Trevor Ziman 2

  3. Slide 3: Asia Pacific Revenue Growth 2001 - 2013

    Asia Pacific Revenue Growth 2001 - 2013 9 000 8 000 7 000 2013 Aspen acquired rights to 6 000 intellectual property R’million 5 000 licenses, net assets and shares in the Infant 4 000 Nutritional portfolio S26 from Nestle. The 3 000 portfolio accounts for annual sales of 2 000 $90 million in Austral

  4. Slide 4: Australian Market in Decline

    Australian Market in Decline IMS Market Sales 14 500 000 000  Government price cuts impacting 14 000 000 000 value of market 13 500 000 000  Further price reductions are 13 000 000 000 inevitable 12 500 000 000  Aspen’s savings and organic 12 000 000 000 growth will mitigate impact of price 11 50

  5. Slide 5: Aspen Australia Outlook

    Aspen Australia Outlook Despite the difficult market conditions, Aspen expects to outperform the market due to the following:  S26 Nutritional acquisition to produce synergies, and marketing focus that will result in organic growth (no exposure to government price cuts)  Products will continue to

  6. Slide 6: Asia

    Asia  23 million people in Australia versus 4.3 billion in Asia. Population huge and growing rapidly  The Australian pharmaceutical market is worth $14 billion. The Asian Pharmaceutical market is almost $200 billion and growing Asia’s Attraction to Aspen  Emerging middle class – many already loya

  7. Slide 7: Asia Pharmaceutical Market

    Asia Pharmaceutical Market Significant & Growing 250 197.3 200 187.5 KOREA 160.4 KOREA 150 142.1 USD’ billion KOREA 123.1 KOREA JAPAN KOREA JAPAN 100 JAPAN JAPAN JAPAN 50 CHINA CHINA CHINA CHINA CHINA 0 2008 2009 2010 2011 2012 BANGLADESH CHINA HONG KONG INDIA INDONESIA JAPAN KOREA MALAYSIA PAKISTAN

  8. Slide 8: Hong Kong Aspen Regional Hub

    Hong Kong Aspen Regional Hub  Close proximity to all Asian markets Korea  Manage Aspen’s businesses China Japan ◦ Ongoing businesses ◦ Acquisition transitions Taiwan Hong Kong ◦ Business development such Thailand as regional acquisitions, in- Philippines Malaysia licensing & pipeline launches Sing

  9. Slide 9: Growing Aspen In Asia

    Growing Aspen In Asia  Criteria for setting up subsidiaries ◦ Critical mass ◦ Cost comparison: Aspen affiliates vs distributors ◦ Risk vs potential returns  Potential acquisition and in-licensing opportunities more effectively targeted  Subsidiaries established so far ◦ Philippines ◦ Taiwan ◦ Mal

  10. Slide 10: Aspen Up And Running

    Aspen Up And Running Philippines Malaysia Taiwan Pharma market size: $3.1 billion Pharma market size: $1.9 billion Pharma market size: $4.4 billion Population: 97 million Population: 30 million Population: 23 million Economic growth of 6.6% Economic growth of 4.3% Economic growth of 2.31% Pharma mar

  11. Slide 11: Japan Is A Key Opportunity

    Japan Is A Key Opportunity Critical mass exists for subsidiary to be set up  Population: 127 million  World’s 3rd largest economy and second largest pharmaceutical market. Market worth $89 billion growing at 5.1%  Healthcare expenditure: 8.5% of GDP  Rapidly ageing population  Fully reimbursed

  12. Slide 12: On Aspen's Radar

    On Aspen’s Radar China Indonesia Thailand Population: 1.34 billion Population: 237 million Population: 65 million GDP per capita: USD 6,091 GDP per capita: USD 4,666 GDP per capita: USD 9,398 Economic growth of 7% Economic growth of 6.2% Economic growth of 6.4% Pharma market growth of 22% Pharma mar

  13. Slide 13: Aspen Brazil

    Aspen Brazil Presented by Alexandre França 13

  14. Slide 14: Ten largest world economies

    Ten largest world economies 14

  15. Slide 15: Aspen in Brazil

    Aspen in Brazil +2012 1 Calman and Alcachofra 1 took leadership. Prism | project portfolio | 2010 1 integration generating 1 Aspen acquired full 1 More sales than ever. ! control of the Latin 1 Organic growth and ' American businesses ' new products drive 1 acquired in 2008. | performance. 1 Welcome

  16. Slide 16: Aspen and Brazilian Pharma Market

    Aspen and Brazilian Pharma Market Rank USD: 26 billion + 4% EMS (bra) 1 Hypermarcas (bra) 2 Sanofi (fra) 3 Aché (bra) 4 Leader since Novartis (swi) 5 11/2012 Eurofarma (bra) 6 Teuto (bra) 7 Takeda (jpn) 8 Bayer (ger) 9 Leader União Q. (bra) 10 since 2012 2013 07/2012 ASPEN 63 41 Source : IMS - Septe

  17. Slide 17: Aspen Brazil: Continuous Growth

    Aspen Brazil : Continuous Growth ZAR’millions 503 575 817 17

  18. Slide 18: Milk of Magnesia – Aspen Impact

    Milk of Magnesia – Aspen Impact Milk of Magnesia unit sales 2 150 000 2 100 000 2 050 000 2 000 000 Units 1 950 000 1 900 000 1 850 000 1 800 000 1 750 000 1 700 000 GSK Aspen 18

  19. Slide 19: Aspen's growth drivers

    Aspen’s growth drivers  Local & Global acquisitions  Continuous organic growth  MSD & GSK acquisitions to bring credibility  Pipeline based on main categories supports our growth  Profit oriented  People development and teamwork Profit, Process and People 19

  20. Slide 20: Why are we going to succeed in Brazil?

    Why are we going to succeed in Brazil? Because ….  We do know how to sell our products  We do know our numbers  We have got the right people  We don´t give up  We want to make ASPEN BRAZIL bigger and bigger  We are 20

  21. Slide 21: Brazil team

    Brazil team aspen 21

  22. Slide 22: Aspen Spanish Latin America

    Aspen Spanish Latin America Presented by Carlos Abelleyra Cordero 22

  23. Slide 23: Content

    Content  Spanish Latam Region Overview  Aspen’s history in Latin America  Outlook  Spanish Latam medium term targets 23

  24. Slide 24: Spanish Latam Region Overview

    Spanish Latam Region Overview Expenses per capita in Health & Growth (USD) Source: WHO – Global Health Expenditure Databes (varying years from 2004 to 2011) http://apps.who.int/nha/database/PreDataExplorer.aspx?r=1&d=1 Source: IMS Health, MIDAS, MAT Dec 2012; Retail Market only; List prices 24

  25. Slide 25: Spanish Latam Region Overview

    Spanish Latam Region Overview USD billions CAGR 2008-2012 Latam* 13.9% Japan Asia Europe North America 0 5 10 15 LATAM Second fastest growing region in sales Source: WHO – Global Health Expenditure Databes (varying years from 2004 to 2011) http://apps.who.int/nha/database/PreDataExplorer.aspx?r=1&d=

  26. Slide 26: Aspen Footprint in Spanish Latam

    Aspen Footprint in Spanish Latam Building identity and ownership IMF, Merck, GSK Acquisitions 2 9 Aspen Subsidiaries Commercialization 26

  27. Slide 27: Outlook

    Outlook Key Success Factors  Focus on key Aspen Therapeutic Areas  Right level of investment & flawless execution  Product portfolio upgrade & revamp product pipeline Sales Projection Full Year 1 after all the acquisitions are in place Key Challenges >USD 400M  Position Aspen as a Key Player in

  28. Slide 28: Spanish Latam - Medium term targets

    Spanish Latam - Medium term targets Revenue > $ 400m USD Revenue = $ 800m USD Ranking (IMS) > # 19 TOP 10 $ 0.37m USD per Head 2014 = 1,060 $ 0.5m USD / Head SKUs > 865 + SKUs > 1,200 + Markets > 25 Markets > 25 Aspen affiliates > 9 Aspen affiliates > 12 28

  29. Slide 29: Aspen Europe CIS

    Aspen Europe CIS Presented by Michael Crow 29

  30. Slide 30: Europe CIS - 50 markets, approx. 800million population

    Europe CIS - 50 markets, approx. 800million population …economically diverse • EU mature + Norway, Switzerland – Highly regulated, low growth but high value • Europe emerging (CEE markets) – EU regulated, low value but growth potential • Russia CIS, Turkey – Volatile, increasingly protected but high

  31. Slide 31: Aspen's presence today in Europe

    Aspen’s presence today in Europe Distributor markets Manufacturing Sites 31

  32. Slide 32: Aspen Europe CIS: January 2014

    Aspen Europe CIS: January 2014 …400 Aspen thrombosis sales representatives …in 17 markets covering 85% total sales …3 manufacturing sites Aspen Europe Commercial Aspen CEE Commercial Aspen Russia CIS Commercial Distributor markets Manufacturing Sites 32

  33. Slide 33: 2013/14 Europe CIS Sales Split

    2013/14 Europe CIS Sales Split* Other *2013 GSK Budget *2012 MSD Actual Hormones / Women’s *2013/14 Aspen Budget 6% Health 10% Oncology 11% 73% Thrombosis Thrombosis is our core focus 33

  34. Slide 34: The thrombosis opportunity

    The thrombosis opportunity…  €3.2billion thrombosis market in EU CIS ◦ LWMH’s = €2.1billion, growing +1.26%* ◦ Growth rates increase towards the east  Volume / Value of the thrombosis market varies significantly between countries  Fraxi / Arixtra share of market varies significantly across countr

  35. Slide 35: Thrombosis market by value in Europe CIS

    The thrombosis market presents a contrasted picture in Europe CIS, both in value... The EU5 account for 74% of sales but CEE & CIS growing much faster, especially Russia where we will have approx 100 thrombosis sales reps Total market value by country – Sales 900.00 100.0% 800.00 80.0% 700.00 Growth

  36. Slide 36: Thrombosis market by volume

    ...as well as in volume The EU5 continue to dominate the market from a volume perspective, while growth is stronger in Russia, Bulgaria and Hungary among others Total market volume by country – Units 80 30.0% 70 25.0% 20.0% 60 Growth – 3yr CAGR 08.11-13 15.0% 50 Unit volume - (m) 10.0% 40 5.0% 30 0.

  37. Slide 37: Development of the business

    Development of the business…  Strategy - To capture LMWH market share  How - by being experts in thrombosis ◦ Focus…. − Reinvigorate promotion without compromise − Prioritise resources towards volume, value and share growth − Defend against orals and generic ◦ Flexible…commercial and promotional a

  38. Slide 38: Key takeaways

    Key takeaways  Aspen Europe CIS starts January 2014  Looking forward we have ◦ opportunities to grow and ◦ value to defend ◦ and a footprint to expand on  Most important of all, we will have the People to make it happen 38

  39. Slide 39: Aspen Global Incorporated

    Aspen Global Incorporated Presented by Samer Kassem 39

  40. Slide 40: The Story of a Journey

    The Story of a Journey 40

  41. Slide 41: The Story of a Journey

    The Story of a Journey 41

  42. Slide 42: The Story of a Journey

    The Story of a Journey 42

  43. Slide 43: The Story of a Journey

    > ® Cc i =) O re) © i Oo a O ~ Y) ® &— -

  44. Slide 44: Mauritius: Vacation destination or infrastructure for an agile Global entity?

    Mauritius: Vacation destination or infrastructure for an agile Global entity? 44

  45. Slide 45: AGI's Objectives

    AGI’s Objectives  AGI manages and maintains the intellectual property rights, regulatory and Launch strategy of Aspen’s Global Brands* as well as performs all of the supply related operations.  AGI has an important role in facilitating the internationalization strategy of Aspen  AGI acts as a hol

  46. Slide 46: '& Kopleore Anais

    '& Kopleore Anais 46

  47. Slide 47: AGI's Diversity

    AGI’s Diversity Gender Split 52% 48% Country Of Origin Mauritians: 70% Non- Mauritians: 30% 47

  48. Slide 48: AGI's Diversity

    AGI’s Diversity 13 Nationalities English French Lebanese South African Ukrainian Russian Mauritian Danish Indian Kenyan Irish Greek American 22 Languages English Afrikaans Creole Danish Dutch French German Gujarati Hindi Lebanese Malayalam Marati Norwegian Russian Sepedi Swahili Swedish Telugu Ukran

  49. Slide 49: AGI in numbers

    AGI in numbers  The largest company in Mauritius  Managed over 60 projects including 7 major deals  Transferred distribution in over 100 countries and managed the transfer of over 2000 SKUs to our supply chain  Supported 3,800 MA submissions related to deals and projects  Current management of

  50. Slide 50: Supply Chain Network

    Supply Chain Network 21 APIs, 59+ 2063 SKUs API, 5 Secondary 140 API SKUs 39 Secondary Triturate, Packers & 1 Markets on 25 Primary Supply Sites Bulk, Semi LPC in 6 continents Suppliers in in 20 FG, Core 6 countries 10 countries countries Packs, Distributor Distributor Finished Packs PK Distributor

  51. Slide 51: Next Steps

    Next Steps  Continue efficient and effective management of current operations  Delivery on existing margin improvement projects  Integrate and transition new deals with Merck and GSK  Implement projects to drive further savings and efficiencies 51

  52. Slide 52: Disclaimer

    Disclaimer Cautionary regarding forward-looking statements This presentation has been prepared by Aspen Pharmacare Holdings Limited based on information available to it as at the date of the presentation. This presentation may contain prospects, projections, future plans and expectations, strategy a

Aspen Pharmacare Holdings — Investor Presentation (November 2013) on 6ix